International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 2, Issue 15 | Research Article | Open Access
Pastore F*
Pastore F1*, Nardone V2, Grassi R2, Mastrandrea L3, Di Gennaro D3, Muto M4, Porri G5, De Rosa N5, Conte M6, Iorio V6, Argenone A7, Gherardi F8, Muto P8
1Radiation Oncology, Emicenter, Napoli, Italy
2Radiation Oncology, Department of Precision Medicine, University of Campania L. Vanvitelli, Italy
3Radiation Oncology, Ruggi d’Aragona Hospital, Salerno, Italy
4Radiation Oncology, AO San Pio Hospital, Avellino, Italy
5Radiation Oncology, Aktis, Marano (Na), Italy
6Radiation Oncology, Emicenter, Casavatore (Na), Italy
7Radiation Oncology, AO San Pio Hospital, Benevento, Italy
8Radiation Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale, Naples, Italy
Fulltext PDFRadiation therapy (RT), for patients with non-melanoma skin cancer (NMSC), achieve high LC rates and favourable toxicity profile. The AIRO Campania board presents retrospective data collection of NMSC patient treated with exclusive RT. Tumor response was defined according to RECIST criteria and toxicity according CTCAE v 0.5 scale. Local control (LC) was defined as stable disease, complete or partial response to treatment. A total of 263 patients treated from January 2019 to March 2022 were enrolled from eight Centres. The most frequently used fractionation (24%) was 40 Gy delivered in 5 fractions. At a median follow-up of 11 months, LC was achieved in 89% of patients. G3 toxicity rate was only 5%. The data reveal an effective collaboration in the creation of the first retrospective database of NMSC patients in Campania. We need to standardize following current guideline and as for follow-up data, clinical and radiologic response criteria.
Radiation therapy (RT); The AIRO Campania board; Local control (LC)
Pastore F, Nardone V, Grassi R, Mastrandrea L, Di Gennaro D, Muto M, et al. Curative Radiotherapy Treatment for Non Melanoma Skin Cancer: The Airo Campania Experience. Int Clinc Med Case Rep Jour. 2023;2(11):1-4.